Diagnosing aggressive prostate cancer by spectroscopic photoacoustic tomography

通过光谱光声断层扫描诊断侵袭性前列腺癌

• 批准号: 8832711
• 负责人: Ji-Xin Cheng
• 金额: $ 21.3万
• 依托单位: VIBRONIX, INC.
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-05-01 至 2016-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8832711
• 关键词: Address; Adult; Algorithms; Appearance; Biological Markers; Blood; Businesses; Cancer Detection; Cancer Patient; Cancerous; Cessation of life; Chemicals; Cholesterol Esters; Clinic; Clinical; Color; Diagnosis; Diagnostic Procedure; Digital Rectal Examination; Evaluation; Feasibility Studies; Foundations; Gland; Gleason Grade for Prostate Cancer; Goals; Grant; Histology; Image; Imaging technology; Indiana; Malignant Neoplasms; Malignant neoplasm of prostate; Maps; Measurement; Measures; Methods; Modality; Molecular; Near-Infrared Spectroscopy; Needle biopsy procedure; Operative Surgical Procedures; Pathology; Patients; Pattern; Phase; Physicians; Procedures; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Proteins; Research; Resolution; Sampling; Screening for Prostate Cancer; Small Business Technology Transfer Research; Specificity; System; Technology; Testing; Tissues; Transrectal Ultrasound; Tumor Volume; Ultrasonic Transducer; Ultrasonography; Universities; Urogenital Cancer; Urology; accurate diagnosis; base; cancer diagnosis; cancer imaging; chemical bond; design; in vivo; male; medical schools; men; miniaturize; minimally invasive; phase 2 study; photoacoustic imaging; prevent; professor; public health relevance; tomography; tumor

DESCRIPTION (provided by applicant): Prostate cancer (PCa) is the No. 2 killer among male cancer patients. The ultimate test is based on transrectal ultrasound guided needle biopsy and histological examination of fixed prostate tissues. This conventional diagnostic procedure is invasive, missing 30% cases of cancer due to small sampling volume. Moreover, it leads to an overtreatment of patients due to low specificity in diagnosing aggressive cancers. To address this pressing need, Vibronix, Inc. and its research partners at Purdue University and Indiana University School of Medicine propose to develop a spectroscopic vibrational photoacoustic tomography (VPAT) system for PCa diagnosis using cholesteryl ester accumulation as biomarker. As an Indiana-based small business, Vibronix, Inc.'s long-term goal is to bring the VPAT technology from bench top to bedside. The central hypothesis of this STTR project is that the VPAT system can measure the size of the tumor in intact prostate tissue. Vibronix, Inc. along with its research partners have formed an interdisciplinary team to test this hypothesis. Dr. Ji-Xin Cheng (PI) the first to demonstrate CE accumulation as a marker for PCa. His lab also demonstrated the first VPAT system 6. Dr. Liang Cheng (MD) is a professor in Department of Pathology in Indiana University School of Medicine (IUSM) and will perform pathological grading of the prostatectomy samples. Dr. Timothy Masterson (MD) is an Assistant Professor of Urology and specializes in the treatment of adult genitourinary cancers. The proposed hypothesis can be tested through the following specific aims: (1) Demonstrate a miniaturized VPAT system with an imaging depth of 3 cm. (2) Demonstrate spectroscopic VPAT imaging of intact prostate gland using CE as a biomarker to differentiate normal and cancerous prostate tissues, and the measurement of the tissue volume. Deliverable: Upon successful design and evaluation of the transrectal spectroscopic VPAT system, we will have generated a new imaging technology for measure the prostate tumor volume in an intact prostate gland using CE as a biomarker. This advance will pave the foundation for a phase II study in which in vivo VPAT imaging will be performed and CE accumulation will be correlated with aggressiveness of PCa. Eventually, our VPAT technology, in a minimally invasive manner, would assist a physician to diagnose PCa objectively and to decide whether prostatectomy surgery is needed.

描述（由申请人提供）：前列腺癌（PCA）是男性癌症患者的第二名杀手。最终测试基于经直肠超声引导的针头活检和固定前列腺组织的组织学检查。这种常规的诊断程序是侵入性的，由于抽样量较小而缺少30％的癌症病例。此外，由于诊断侵袭性癌症的特异性较低，因此导致患者过度治疗。为了满足这一紧迫的需求，Vibronix，Inc。及其研究伙伴在普渡大学和印第安纳大学医学院提出，使用Cholesteryl Ester积累为生物标志物，开发了一种用于PCA诊断的光谱振动光声断层扫描（VPAT）系统。作为一家总部位于印第安纳州的小型企业，Vibronix，Inc。的长期目标是将VPAT技术从台式上的顶部带到床边。该STTR项目的中心假设是VPAT系统可以测量完整的前列腺组织中肿瘤的大小。 Vibronix，Inc。以及其研究伙伴组成了一个跨学科团队来检验这一假设。 Ji-Xin Cheng博士（PI）第一个证明CE积累为PCA标记的人。他的实验室还展示了第一个VPAT系统6。LiangCheng博士（MD）是印第安纳大学医学院病理学系（IUSM）的教授，将对前列腺切除术样本进行病理分级。蒂莫西·马斯特森（Timothy Masterson）博士（医学博士）是泌尿外科助理教授，专门研究成人泌尿生殖器癌的治疗。提出的假设可以通过以下特定目的进行检验：（1）展示一个小型VPAT系统，成像深度为3 cm。 （2）使用CE作为生物标志物来区分正常和癌性前列腺组织以及组织体积的测量来证明完整前列腺的光谱VPAT成像。可交付：在对跨直直直直径VPAT系统的成功设计和评估后，我们将生成一种新的成像技术，以使用CE作为生物标记物在完整的前列腺中测量前列腺肿瘤的体积。这一进步将为II期研究奠定基础，在该研究中将进行体内VPAT成像，并且CE积累将与PCA的侵略性相关。最终，我们的VPAT技术以微创的方式将有助于医生客观地诊断PCA，并决定是否需要前列腺切除术手术。